The long-term solutions for moving HIV prevention and treatment tools from the lab to all those in need can help people living with HIV to thrive and not just survive.

Even today 25% of people living with HIV are not on treatment and last year (2020), 690,000 people died from AIDS related illnesses and 1.5 million were newly infected with HIV.
From research to implementation is a long and arduous journey with too many stumbling blocks. Many discussions at the recently concluded 11th International IAS Conference on HIV Science (IAS 2021) centred around the challenges, and solutions thereof, to speed up the processes to get any new product into people’s hands.
First and foremost is getting the product approved by global regulatory bodies like the WHO, US FDA and EMA. Next comes individual countries’ willingness to endorse the product (and different countries may have different regulatory processes).
Countries take quite some time to understand the guidance given by WHO and others, and then disseminate that information to the service providers. This process usually could take about a year. So national templates must be developed early on for countries to adapt quickly.
Clear, accurate, and reliable information, needs to get to all people living with HIV to make informed decisions. So, providing a complete knowledge and information to the communities about any new product is important.
High cost of the product is another deterrent for its uptake. Unless they are subsidised or their generic equivalents are made available, product uptake is not increased.
All communities should benefit from the results of science, else public health value of these scientific advancements will be very limited.
Source-Medindia
MEDINDIA








